Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

r patients.

The first Phase l study showed that TB-403 was safe and well tolerated,

with a pharmacokinetic profile which would allow it to be developed as

a treatment for cancer. TB-403 has moved into a Phase Ib trial. This

study will look at the tolerability, pharmacokinetics and

pharmacodynamics of TB-403 in patients with advanced cancer.

- Microplasmin: Positive results announced in Phase II

clinical trials for ophthalmic indications. Positive results were

reported in ThromboGenics' Phase IIb MIVI III trial in patients with a

number of back of the eye conditions. The trial showed that the most

effective dose of microplasmin studied (125 micro g) was able to

resolve the underlying disease in approximately 30% of patients and

consequently achieved the avoidance of surgical intervention in those

patients.

Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.

Investor Highlights

ThromboGenics has continued to work to broaden the Company's shareholder base. In July, ThromboGenics announced the acquisition of an 8% stake in the Company by a group of private investors based in Belgium in a transaction coordinated by Petercam. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics' largest shareholder. Biggar intends to remain an important shareholder in ThromboGenics for the long term.

Financial Summary

- In the first six months of 2008, revenue amounted to EUR30.3

million. This much higher level of revenue is due to Roche's upfront

payment following the signed co-development deal on TB-403. Operating

expenses were EUR13.0 million in the first half, the majority of which

were due
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
(Date:5/5/2015)... Research and Markets ( ... the "Separation Systems Market in Biotechnology" ... Macromolecules which include protein, RNA, DNA and ... into smaller molecules, during production of commercially ... advanced systems like centrifugation, liquid chromatography, electrophoresis, ...
(Date:5/5/2015)...  Renova™ Therapeutics, a biopharmaceutical company developing gene ... chronic diseases, has engaged RAND Health Advisory Services ... the healthcare patterns of multiple advanced heart failure ... to characterize the impact the company,s lead product, ... of patients and the overall health care system. ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 A comment ... a wide range of key photonics technologies – regulations ... competitiveness of U.S. industry. To help the community understand ... 12 May on the proposed changes to U.S. ... covered by International Traffic in Arms Regulations (ITAR). , ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4
... Inc. ("Company") (OTCQB: SVFC.PK) announced today that the Company has ... of Thailand, http://www.StemCells21.com . Stem Cells 21 is ... the College of Anti-ageing Medicine and a member of ... Managing Director for the Stem Cells 21.  They have ...
... University of Southern California Marshall School of Business, ranked among ... Marshall School of Business Leadership Summit to be held ... at Los Angeles, newest landmark, the JW Marriot—just steps away ... A new dynamic format will keep interest high ...
... is Preeclampsia Awareness Month and to build awareness of ... period, thousands of families in 36 cities in the ... The Preeclampsia Foundation is holding the Promise ... help provide patient support and education, raise public awareness, ...
Cached Biology Technology:IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand 2USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Preeclampsia Awareness Month Marked By Promise Walks in 36 Cities 2Preeclampsia Awareness Month Marked By Promise Walks in 36 Cities 3
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... problems, kidney disorders or high blood pressure could benefit ... new "smart" holograms, which can detect changes in, for ... and more reliable, write Chris Lowe and Cynthia Larbey ... recording of an optical interference pattern created when laser ...
... - Rainfall data from a NASA satellite show that summertime ... than on weekends. Scientists say air pollution from humans is ... and the day of the week is evident in data ... Midweek storms tend to be stronger, drop more rain and ...
... has demonstrated the role of a gene important to ... that requires coordination of differentiation of immature neural cells ... numbers. Until now, the mechanisms regulating these distinct cellular ... will be published in the Feb. 15 issue of ...
Cached Biology News:'Smart' holograms help patients help themselves 2NASA data link pollution to rainy summer days in the southeast 2NASA data link pollution to rainy summer days in the southeast 3Trainor Lab characterizes gene essential for prenatal development of nervous system 2
...
See product name for description....
... Staining Kit, 1. Select from homogeneous ... peptides on denaturing, native, and isoelectric ... with precast gels, buffer strips, and ... that of radioisotopes with ready-to-use silver ...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Biology Products: